Pharmacotherapy for erectile dysfunction

Area of Science:

• Pharmacology
• Urology
• Sexual Medicine

Background:

• Advances in understanding penile erection physiology and biochemistry have driven pharmacotherapy breakthroughs for erectile dysfunction (ED).
• Current treatments focus on molecular and cellular mechanisms of action for centrally and peripherally acting drugs.

Purpose of the Study:

• To provide guidelines on the state-of-the-art knowledge regarding the mechanisms of action of drugs used in ED pharmacotherapy.
• To consolidate expert opinion on the molecular and cellular basis of ED drug efficacy.

Main Methods:

• An international consultation involving over 200 multidisciplinary experts from 60 countries over two years.
• Expert opinions were formed through grading evidence-based literature, committee discussions, and public debates.
• A dedicated committee of 25 experts from 10 countries focused on pharmacotherapy for erectile dysfunction.

Main Results:

• Oral phosphodiesterase type 5 (PDE5) inhibitors exhibit high affinity for the PDE5 enzyme, blocking cyclic guanosine monophosphate (cGMP) access and facilitating smooth muscle relaxation.
• PDE5 inhibitors, varying in potency and pharmacokinetics, elevate cGMP levels post-sexual stimulation.
• Centrally acting drugs, such as the dopamine (D2) receptor agonist apomorphine, enhance sexual behavior by acting on the hypothalamus.

Conclusions:

• Further research is essential for developing innovative central and peripheral pharmacotherapeutic agents for safe and effective erectile dysfunction treatment.
• The current understanding highlights the distinct mechanisms of PDE5 inhibitors and central enhancers in ED management.